Clinical Trials Logo

Endometrial Neoplasms clinical trials

View clinical trials related to Endometrial Neoplasms.

Filter by:

NCT ID: NCT05912972 Recruiting - Ovarian Cancer Clinical Trials

Development and Management of Registry in Patients With Gynecologic Cancer in Korea

Start date: October 21, 2022
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to identify and analyze the characteristics, treatment trends, prognostic factors and survival prognosis of Korean gynecologic cancer patients. Ultimately, the final goal is to contribute to the development of safe surgical methods and treatment for gynecologic cancer to improve survival rates.

NCT ID: NCT05902988 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Start date: October 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

NCT ID: NCT05887492 Recruiting - Breast Cancer Clinical Trials

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Start date: June 12, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question[s] it aims to answer are: - the recommended dose for Phase 2 - to evaluate the safety and tolerability of the combination therapy - to determine the pharmacokinetics of TNG260 - to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.

NCT ID: NCT05876130 Recruiting - Endometrial Cancer Clinical Trials

Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

To investigate the non-inferiority of disease-free survival in women who received hypofractionated intensity-modulated whole pelvic radiation therapy (2.5 Gy x 16 fractions) after curative surgery for stage III endometrial cancer.

NCT ID: NCT05858736 Recruiting - Colorectal Cancer Clinical Trials

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

PRESERVE-009
Start date: July 11, 2023
Phase: Phase 1
Study type: Interventional

AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).

NCT ID: NCT05857631 Recruiting - Cervical Cancer Clinical Trials

Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study

PARCERII
Start date: May 29, 2023
Phase: N/A
Study type: Interventional

The primary aim of the trial is to investigate the late effects of hypofractionated external radiation (39 Gy in 13 fractions) in patients requiring post-operative radiation for early-stage cervical and endometrial cancers.

NCT ID: NCT05855941 Recruiting - Endometrial Cancer Clinical Trials

Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)

PRODIGYN
Start date: May 23, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are: - Does advanced medical imaging predict survival? - Can advanced medical imaging improve radiotherapy target planning? - Are advanced medical imaging results associated with risk markers found in tumor tissue? Participants will - Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months. - Be subject to clinical follow-up for five years.

NCT ID: NCT05833321 Recruiting - Sarcopenia Clinical Trials

Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer

SARCO-GYN
Start date: November 20, 2022
Phase: N/A
Study type: Interventional

Prospective monocentric study, non-randomized of the detection of sarcopenia in clinical practice in patients with ovarian or endometrial cancer requiring systemic oncological treatment. main question : Identify the criteria correlated with the presence of sarcopenia (defined by the measurement of the IMS by the CT-X method in L3) among the impedancemetry and the HAS malnutrition criteria. Data collection will be done at 6 months, 12 months after the date of inclusion.

NCT ID: NCT05827614 Recruiting - Breast Cancer Clinical Trials

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications

POTENTIATE
Start date: March 24, 2023
Phase: Phase 1
Study type: Interventional

BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies.

NCT ID: NCT05819892 Recruiting - Endometrial Cancer Clinical Trials

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Start date: July 17, 2023
Phase: Phase 1
Study type: Interventional

To learn if chemotherapy given in combination with radiation therapy, followed by maintenance therapy, can help to control endometrial cancer. The safety and effects of this study treatment will also be studied